Stay updated with breaking news from Toronto Memory Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The relentless pursuit of detecting Alzheimer’s has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.
Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2023--
– First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose – – ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile – – Multiple-dose Portion of Study, Part B, Being Initiated in Approved Regions –